Fritextsökning
Artiklar per år
Innehållstyper
-
Genovis ramps up in ADC technology: “An area where we’re seeing very strong interest”
With new products and an expanded licensing agreement in hand Genovis now has a partly new focus for its operations: ADCs – or antibody‑drug conjugates.
-
Genovis tillväxtresa fortsätter inom antikroppskonjugat – ”Ett väldigt bra momentum”
Med nya produkter och ett utvidgat licensavtal i bakfickan har Skånebolaget Genovis ett delvis nytt fokus för sin verksamhet: ADC:er – eller antikroppskonjugat.
-
Finland leads the way in the hunt for international top researchers
Several Nordic initiatives are currently under way to recruit international top researchers. Finland is making its largest national investment ever in attracting leading talent from abroad.
-
Ilska hos Moderna efter FDA:s vaccinnobb
Modernas aktie föll på tisdagen sedan FDA vägrat att granska bolagets ansökan om godkännande av en nytt mRNA-baserat influensavaccin. Företaget är starkt kritiskt och ifrågasätter myndighetens ändrade hållning.
-
Dying man saved by artificial lung system
An external artificial lung system kept a critically ill man alive for two days until he could undergo a lung transplant. In the longer term, researchers hope the technology could transform the treatment of patients with life-threatening lung disease.
-
Study: Autism as common in girls as in boys
Autism may be just as common in girls as in boys, but girls are diagnosed significantly later and less often during childhood, according to a large Swedish registry study.
-
Top 10 biggest drug launches 2026
Two presumed sales rockets – both in obesity and type 2 diabetes – top a list of potential blockbusters expected to launch in the United States in 2026.
-
Cell-free cartilage from Lund could pave the way for new bone transplants
Researchers at Lund University have developed a new method for repairing large bone defects, based on laboratory-engineered, cell-free cartilage grafts. The technique has so far been tested in animal models, and the results have attracted considerable interest internationally.
-
Döende man räddades av artificiellt lungsystem
Ett externt artificiellt lungsystem höll en svårt sjuk man vid liv i två dygn tills han kunde genomgå lungtransplantation. På sikt hoppas forskare förändra behandlingen av patienter med livshotande lungsjukdom.
-
Gene therapies on clinical hold after tumour found in five‑year‑old
The development of a brain tumour in a study participant has led the FDA to temporarily halt two ongoing gene therapy programs. The affected company, Regenxbio, immediately lost nearly one‑fifth of its market value.
-
Swedish drug development projects in Phase III – studies to keep an eye on
Developing new medicines is, as we know, a lengthy and uncertain process, and only a fraction of all projects ever reach late clinical phase. But it does happen – and here we highlight a number of promising Swedish drug candidates currently in Phase III that are worth watching more closely.
-
“The US matters most – even in times of turbulence”
Tariffs, geopolitical uncertainty and rapidly changing trade conditions mean that Swedish life science companies need more routes into global markets – and faster support to understand what actually applies. That is the view of Johan Chun, newly appointed Head of Industry at Business Sweden.
-
Studie: Kraftigt ökad demensrisk vid upprepade huvudtrauman
Personer som drabbas av kronisk, traumatisk hjärnskada – särskilt vanlig hos vissa idrottsutövare – löper fyrdubblad risk att drabbas av demens, enligt en ny studie.
-
Positive outcome in phase III for Sanofi’s eczema treatment
The antibody amlitelimab shows positive Phase III data as a treatment for atopic dermatitis. France‑based Sanofi now plans to submit global regulatory applications before the end of the year.
-
Atrogi on its challenger to GLP-1: “Now we are stepping forward”
A new approach to treating type 2 diabetes and obesity is taking shape in a laboratory just a stone’s throw from the Karolinska Institute. At Atrogi, researchers are developing a potential challenger to today’s GLP-1.
-
Diamyd och Northx i samarbete för att ta diabetesläkemedel vidare
Diamyd Medical inleder ett samarbete med Northx Biologics. Syftet är att kratta vägen för en potentiell framtida kommersialisering av retogatein, bolagets läkemedelskandidat inom typ 1-diabetes.
-
Lungsjukdom utan cigaretter: Dammiga branscher pekas ut i studie
Damm från betong, sten och metall höjer risken för emfysem, enligt en svensk studie.
-
List: The companies behind 38 new pharmaceutical substances in the EU
In 2025, the European Medicines Agency (EMA) recommended 104 medicines for approval. Of these, 38 contained a new active substance that had never before been authorised in the EU. Life Science Sweden has mapped the companies and countries behind the new substances.
-
Novo Nordisk Foundation commits billions to Danish life science incubator
The Novo Nordisk Foundation grants up to DKK 5.5 billion to life science and deep‑tech incubator Bioinnovation Institute (BII) in Copenhagen.
-
Investor Network Backs Early-Stage Nordic Innovation
Life Science Invest is expanding into the Nordic region and has secured SEK 31 million to invest in early-stage research companies. The capital will be invested in around ten life science companies over the coming year.
-
Fourteen US-based top researchers recruited to Sweden
Sweden has set its sights on America’s top scholars – and it seems to work. By the end of 2025, fourteen leading U.S.-based researchers had already been won over to Swedish universities.
-
Obesity dominates as future blockbusters are identified
Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.
BREAKING